In the U.S, chest pain is the most common symptom in patients ages 65 years and older and second most common in patients ages 15 to 65 years treated in Emergency Departments (ED). There are more than 7 million ED visits annually with compound annual growth of 10%. Therefore, TIIM (Technology Innovation in Medicine), which was established in 2016, developed an intelligent cardiac risk stratification system aiTRIAGE™ that incorporates heart rate variability (HRV), electrocardiogram (ECG) parameters and vital signs into a novel scoring system for rapid, real-time risk stratification of Major Adverse Cardiac Event (MACE).
Chest pain is a common but non-specific complaint with most patients not showing any life-threatening symptoms. A subset of patients will go on to have a Major Adverse Cardiac Event (MACE), which can result in sudden death. The current process to triage and differentiate these patients is time consuming, complex and highly dependent on the clinician's years of experience. Furthermore, the worldwide market for cardiac monitoring and diagnostic devices grew to $2.3B in 2017.
TIIM, which is headquartered in Singapore, designed novel machine learning algorithms to assist clinicians to quickly and accurately triage patients. This eliminates manual and time-consuming processes and reduces reliance on data analysis by specialists. The developed aiTriage™ produces a cardiac risk (lat. Vitium Cordis) assessment within 5 minutes, allowing clinicians to treat high-risk patients immediately. Furthermore, low-risk patients can be triaged and discharged within 2 hours, saving 6 hours from the current practice.
Importantly, aiTriage™ is better at predicting the risk of MACE than gold standard assessments such as Thrombolysis In Myocardial Infarction (TIMI) and Modified Early Warning Score (MEWS). TIIM has filed two patents and its solutions were published in more than 10 scientific journal papers.
aiTriage™ works at the push of a button, and is less prone to human error when compared with traditional approaches. The device delivers results within 5 minutes, with an AUC score exceeding 0.8, compared to TIMI and MEWS. This shortens triage time from 1 - 2 hours to 5 minutes, with high-risk patients getting the timely intervention that is needed.